Professional Documents
Culture Documents
1st Shifting Period NOTE: Should there be any discrepancies between this table and whats written in the transes, please consult KATZUNG for confirmation and go instead with whats indicated in the textbook. Thank you!
Indications Indications
anti-diarrheal, antisialogogic, antidote to muscarinic poisoning for bradycardia in acute myocardial infarction for routine preoperative medications to counter the increase in airway secretions and laryngospasms induced by anesthetics anti-spasmodic, anti-motion sickness for reduced amnesia associated with surgical or obstetric delivery for routine preoperative medications to counter the increase in airway secretions and laryngospasms induced by anesthetics anti-spasmodic Anti - parkinsonism mydriatic, cycloplegic for synechia (adhesion in uveitis and iritis)
Contraindications Contraindications
Angle-closure glaucoma Benign Prostatic Hyperplasia Gastric ulcer (because of slowing of gastric emptying time, causing increased gastric secretions and possible aggravation of gastric ulcer)
Methacoline
Scopolamine
rapidly and widely distributed in the CNS, where it has a greater effect there than other antimuscarinic drugs.
Carbachol
Since the blockade produced by these drugs is reversible, their effects can be overcome by increased concentrations of acetylcholine or other muscarinic agonists.
Because they do not block nicotinic receptors, these drugs have little to no action at skeletal neuromuscular junctions or autonomic ganglia. Muscarinic receptors are constitutively active, and drugs that block the actions of due to acetylcholine are Section Tachycardia Juria 2D Batch 2014 the Genitourinary System sensitivity of inverse agonists that to sinoatrial of detrusor Stimulation node shift the equilibrium of muscarinic receptor muscle and relaxation of the receptor to its blockade and (particularly trigone bladder inactive state. the prejunctional M1 muscles increased Most sensitive in
Also used for complete ophthalmologic examination through induction of temporary ciliary PHARMACOLOGY: COMPREHENSIVE Page 2 of 29 paralysis post-op ileus, reflux esopahagitis,
ADRENERGIC AGONISTS
Mechanism of Action
Phenylephrine Milodrine Clonidine Methyldopa Norepinephrine Phenylephrine Methoxamine Epinephrine Isoproterenol Albuterol Metaproterenol Terbutaline Isoproterenol Epinephrine Phenylephrine Apraclonidine Brimonidine Ritodrine Terbutaline Ephedrine Psuedoephrine Amphetamine Methylphenidate Dexmedetomidine Modafinil Mitodrine Ephedrine Eyes mydriasis, cyclopegia, decrease aqueous humor production Cardiovascular System vasoconstriction, (+) inotropy and chronotropy Respiratory System bronchodilation Gastrointestinal Tract decrease motility and secretion GUT slow voiding and urinary retention Glands decrease sweat, lacrimal, nasopharyngeal constriction CNS - stimulant Endocrine Beta - increase lipolysis, glycogenolysis, insulin Alpha - inhibit or opposite alpha
Adverse Effects
Indications
Nasal congestion Chronic orthostatic hypotension Hypotension Hypertension Hypertension Acute hypotension Acute hypotension Acute hypotension Cardiac arrest and complete heart block Cardiac arrest and complete heart block Bronchial asthma Bronchial asthma Bronchial asthma Bronchial asthma Anaphylactic Mydriatic Glaucoma Glaucoma Suppressing premature labor Suppressing premature labor Stress incontinence Stress incontinence Euphoriant ADHD For sedation under intensive care situations and during anaesthesia narcolepsy Chronic orthostatic hypotension Chronic orthostatic hypotension
Contraindications
Other notes
Alpha agonist Alpha 1 agonist Alpha 2 agonist Also found effective in treatment of diarrhea in diabetics with autonomic neuropathy Alpha 2 agonist
Direct Agonist directly bind and activate receptors Indirect Agonists displace stored NE from nerve endings (eg. Tyramine) or inhibit reuptake of release NE (ex. Cocaine and tricyclic antidepressants) 1 increases DAG, IP3 thus activates protein kinases 2 inhibits adenylcyclase thus decreases CAMP 1,2,3 stimulates adenylyl cyclase, increases ATP to CAMP conversion, increases Ca influx inside myocardial cells, promotes relaxation of smooth muscle D1 stimulates adenylcyclase, vasodilation D2 inhibits adenylyl cyclase, opens K channels, decreases Cainfux
ADRENERGIC ANTAGONISTS
Mechanism of Action Alpha receptor Antagonists
Phentolamine Blockade of peripheral dopamine receptors minor clinical importance at present
Adverse Effects
antagonist drugs as stated in mechanism of action may cause orthostatic hypertension,
Indications
Pheochromocytoma, erectile dysfunction
Contraindications
Other notes
Reversible antagonist
Prazosin Labetalol Phenoxybenzamine Terazosin Doxazosin Indoramin Urapidil Chlorpromazine Haloperidol Tamsulosin Alfuzosin Urapidil
Blockade of CNS dopamine receptors clinically significant 1 receptor antagonist drugs vasodilation and tachycardia 1 receptor antagonist drugs acts on receptors on vascular smooth muscle decreased arteriolar and venous tone decreased peripheral vascular resistance and blood pressure vasodilation increased venous pooling in the periphery cannot maintain BP in the upright position orthostatic hypotension 1 receptor antagonist drugs prevent pressor effects of usual doses of agonists 1 selective antagonist drugs convert a pressor to a depressor, response of agonists with both and effects (eg. epinephrine) B receptor antagonist drugs HPN, ischemic heart disease, arrhythmias, endocrinologic and neurologic disorders, glaucoma
vasodilation, (-) inotropy and chronotrophy Respiratory System bronchoconstriction, increase T-B secretion Gastrointestinal Tract increase motility and secretion GUT increase voiding Glands increase sweat, lacrimal and nasopharyngeal secretion CNS decrease migraine and tremors Endocrine inhibit lipolysis glycogenolysis, T4-T3 and increase VLDL
vasodilation leading to tachycardia Eyes blockade of receptors in other tissues leading to miosis Gut blockade of 1 receptors in base of bladder and prostate leading to resistance to urine flow and urinary retention
Chronic hypertension, peripheral vascular disease, urinary obstruction Hypertensive emergencies Pheochromocytoma, peripheral vascular disease Chronic hypertension, urinary obstruction Chronic hypertension, urinary obstruction Chronic hypertension Chronic hypertension, urinary obstruction Chronic hypertension Chronic hypertension Urinary obstruction Urinary obstruction Urinary obstruction
Hypertension Hypertension Hypertension Hypertension Hypertension CHF CHF CHF Glaucoma Glaucoma Hypertension Ischemic heart disease, glaucoma, neurologic disorders Ischemic heart disease, hyperthyroidism, neurologic disorders Ischemic heart disease, heart failure, neurologic disorders Cardiac arrythmia Heart failure Heart failure Glaucoma Glaucoma Glaucoma Glaucoma
Non-selective Selective, non partial agonist Selective, non partial agonist Selective, non partial agonist Selective, partial agonist
Atenolol Nadol
INOTROPIC CARDIOTONICS
A. SS ADRENOCEPTOR & DOPAMINE RECEPTOR AGONISTS Mechanism of Action Organ System Effect Adverse Effects Indications Contraindications Other notes
Dopamine
Stimulation of cardiac 1 adrenoceptorinotrophy >chronotrophy Peripheral vasodilation myocardial demand CO ventricular filling Stimulation of peripheral postjunctional D1 and prejunctional D2 receptors Splanchnic vasodilation and renal Tachycardia, arrhythmia, peripheral vasoconstriction oxygen CVS: hypotension due to receptor stimulation Tachycardia, Arrhythmia, Angina Acute Heart failure Synthetic analog of Dopamine
Dobutamine
B. - NON-SELECTIVE
Epinephrine Norephinephrine
Sympathetic agonist Physiologic antagonist of Histamine-1 receptors Stimulates heart and blood vessels
Drug of choice in anaphylactic shock Does not act on 2 receptors (cannot be used in asthma)
Digoxin
ATPase receptor
Digitoxin
Works in tandem with the Na-Ca exchange channel: inhibition of Na-K ATPase increase in intracellular Na (sodium retention)
Less mortality than digitoxin Former primary drug Very narrow PI FAB ANTIBODY- Antidote to adv effect Half-life:36-40 hours Longer-acting
increase in intracellular Ca (calcium retention) binding of Ca (sequestered from SR) with troponin C excitation-contraction
NON-INOTROPIC CARDIOTONICS
A. VASODILATORS Mechanism of Action
Isosorbide Dinitrate (ISDN) Isosorbide Mononitrate (ISMN)
Adverse Effects
Severe headache due to vasodilation (Monday Disease)
Indications
Contraindications
Other notes
Venodilator
Venodilation
preload
reduction in
SLE (sue to acetylating property in Phase II metabolism either fast or slow) Cyanide Poisoning
Arteriodilator
Reduction in tissue angiotensin levels reduce sympathetic activity (diminution of angiotensins presynaptic effects) Reduces long term remodeling of the heart and vessels reduction mortality and morbidity in
C. ANGIOTENSIN II BLOCKERS Monique Wine Jamie Juria Lenard Section 2D Batch 2014 PHARMACOLOGY: COMPREHENSIVE TABLE OF DRUGS (1st Shifting Period) | Page 6 of 29
LOOP DIURETICS
Furosemide
POTASSIUM-SPARING DIURETICS
Spironolactone Eplerenone Ethacrynic acid Act on the collecting tubule blocks the release of aldosterone Genitourinary: antiandrogenic No antiandrogenic effect Lowering of electrolyte Hyperuricemia Autotoxicity leading to deafness
E. ADRENOCEPTOR BLOCKERS
Bisoprolol Carvedilol Metropolol Propanolol (PO/IM) Esmolol (IO) Reduction in damaging the sympathetic influences in the heart (Tachycardia, arrhythmias) Inhibition of renin release
Carvedilol:
ANTI-ARRHYTHMICS
A. CLASS 1 Sodium-Channel Blocking Mechanism of Action Subgroup 1A
Procainamide
Adverse Effects
Torsade de pointes arrhythmia, syncope, SLElike syndrome Torsade de pointes, Syncope, Cinchonism (headache, dizziness and tinnitus), Nausea, Vomiting Same as quinidine, may precipitate heart failure, atropine-like activity,
Indications
Contraindications
Other notes
Slows
down upstroke of action potential and conduction QRS duration and action potential peripheral resistance Blocker: vascular
Quinidine Disopyramide
Prolongs
Ganglion
Rarely used because of cardiac and extracardiac adverse effects Heart failure, glaucoma Cardiac antimuscarininc effects even more marked than those of quinidine
Supraventricular Arrhythmias
Subgroup 1B
Lidocaine Blocks activated and inactivated sodium channels with rapid kinetics Alters Na, K, Ca conductance, membrane potentials and the concentration of amino acids and nuerotransmitters: (NE, Ach, GABA) Similar to lidocaine Hypotension, Asystole, malignant HPN (rare), CNS manifestations Nystagmus, ataxia, drowsiness, Gingival hyperplasia, Peripheral neuropathy Hypotension and CNS symptoms Ventricular tachycardia Ventricular fibrillation Digitalis Induced Arrhythmias Ventricular Arrhythmia Ventricular Arrhythmias Local anesthetic
Phenytoin
Antiseizure Orally administered Increased metabolism: phenytoin, phenobarbital, rifampin Decreased: cimetidine
Mexiletine
Subgroup 1C
Potent blocker of Na and K channels with slow unblocking kinetics (-) chronotrophic effect Similar to quinidine but does not prolong AP (-) chronotrophic effect Potent sodium channel blocker that does not prolong AP Inhibit catecholamine binding at beta-receptors Direct membrane stabilizing property May cause severe exacerbation of arrhythmia, Brugada Syndrome Metallic taste, constipation,arrhythmia exacerbation Ventricular Arrhythmia Supraventricular Arrhythmia, SV Tachycardia, VT, WolffParkinsons-White Arrhythmias Increased metabolism: propranolol, quinidine. amiodarone Increased metabolism: Warfarin, digoxin, metropolol Withdrawn from market Phenothiazine derivative
Flecainide
Propafenone Moricizine
B.
Propranolol (nonselective) Timolol Metropolol Esmolol (Intraoperative Arrhythmia, IV) Acetabulol (oral)
Multiple actions:
Dronedarone
Class IVAV nodal conduction Class I- depresses Vmax Class II- noncompetitively blocks and
Similar with amiodarone without the thyroid and pulmonary toxicity Dysgeusia (disturbance of taste), sneezing, paresthesia, cough, Atrial Fibrillation
Vernakalant
Structural analog of amiodarone Lacks iodine atoms 1st antiarrhythmic drug to demonstrate a reduction in mortality/hospitalization in patients with AF New Class III drug
Sotalol
refractory period Slows conduction over AV node Does not change QT interval Non-specific -adrenergic receptor-blocker (class 2) Action potential (repolarization) prolonging (class 3) Ibutilide: activate slow inward sodium current Reduces the plateau height of the action potential, slightly shortens action potential, and slightly prolongs total Purkinje fiber AP
hypotension
Ventricular Arrhythmias
100% bioavailability excretion: kidneys IV for Ibutilide Dofetilide: PO, 100% bioavailability
Ibutilide Dofetilide
QT Prolongation
SVT
Verapamil
Adenosine
Digoxin
Peripheral vasodilationtransient hypotension (-) inotropic effects Inhibits the AV node by acting with 1 receptors that opens the adenosine sensitive K channel to hyperpolarize and inhibit AV node and indirectly inhibit calcium channel opening Slowing sinus node discharge rate, shortening atrial refractoriness, prolonging AV nodal refractoriness
See cardiotonics
ANTIHYPERLIPIDEMICS
A. COMPETITIVE INHIBITORS OF HMG-COA REDUCTASE (REDUCTASE INHIBITORS) STATINS Organ System Mechanism of Action Adverse Effects Effects
Pravastatin Inhibits HMG-CoA Reductasepreventing the formation of mevalonate (rate limiting step of sterol synthesis) Induces an increase in high affinity LDL receptors on hepatocytes
Indications
Contraindications
Other Notes
Most effective in reducing LDL together Decrease oxidative stress Decrease vascular inflammation
Lovastatin
Simvastatin
Fluvastatin
Increases both fractional catabolic rate of LDL and livers extraction of LDL precursors (VLDL remnants) from the blood LDL Interfere with the synthesis of lipid intermediates with important biological effects May HDL cholesterol by preventing the geranylation of Rho A and phosphorylation of peroxisome proliferatoractivated receptor (PPARa)- factor that regulates APO A1 transcription
Myopathy cessation upon removal of therapy Hepatic toxicity Cataract Pancreatitis Headache Dizziness Insomnia Blurred vision Dysgeusia Skin rashes
Hydrolyzed in the GIT hydroxyl derivatives Same as Lovastatin More potent than lovastatin Most effective in reducing LDL together Decrease oxidative stress Decrease vascular inflammation Increases stability of atherosclerotic lesion Fluorine containing Almost completely absorbed
Pregnant and lactating women and those likely to become pregnant, hepatic and renal impairment, porphyria, untreated hypothyroidism
Drugs used to lower lipid levels in the body (e.g. cholesterol, LDL)
Rosuvastatin
Fluorine containing 19 hours (long lasting) Same as rosuvastatin but only lasts for 14 hours
Atorvastatin
VLDL and chylomicron or LDL Mosly only modest in LDL Others, especially with combined hyperlipidemia, LDL often Moderate in HDL Effects on plasma levels of lipids: TG Cholesterol
Cholesterol gallstonesreflecting in cholesterol content of bile Hepatotoxicity aminotransferases or alkaline phosphatases Myositis, myopathy, rhabdomyolysis, myoglobinuria, renal failure GIT anorexia, nausea, GI discomfort Skin rashes, urticarial, hair loss Fatigue, headache, impotence Anemia, leucopenia
Hypertriglyceridemia with VLDL or chylomicrons Hypertriglyceridemia- Type I, IV, V Familial combined hyperlipidemi (Type IIb), VLDL is Familial dysbetalipoproteinemia (Type III) Hypertriglyceridemia d/t treatment with viral protease inhibitors
General: Absorption: >90% with meal Plasma protein binding: >95% Excretion: Predominantly as glucoronide conjugates Conjugates: 80-90% in urine; smaller amounts in feces; (Katzung) 60% in urine as glucoronide conjugates; 25% in feces
Monitor: Serum levels of creatine kinase, aminotransferases, and plasma proteins Renal function tests
Blocks sterol transporter NPC1L1 in intestine brush border inhibits reabsorption of cholesterol excreted in bile: LDL and phytosterols Selective inhibitor of intestinal absorption of cholesterol & phytosterols Inhibit absorption of cholesterol both in diet and in bile Actions: LDL, minimal in HDL cholesterol Synergistic with statin Effect on plasma levels of lipoproteins:
Ezetimibe
Familial combined hyperlipidemia when LDL is increased Familial hypercholesterolemia (heterozygous, homozygous)
Readily absorbed Conjugated in intestine to an active glucoronide Enterohepatic circulation T of active metabolite: 22 hrs 80% excreted in the feces Drug interactions: - with fibrates - with cholestyramine
Decreases catabolism of apoA1; reduces VLDL secretion from liver HDL, LDL and TG
VLDL, IDL, LDL, Lp(a), HDL Most effective agent for increasing levels of HDL Only antihyperlipidemic drug that decreases Lp(a) significantly Estrogen and Neomycin also decreases Lp(a) significantly
Skin and mucous membrane: o Harmless cutaneous vasodilator (flush), uncomfortable sensation of wamth and pruritus o Rashes, dry skin, dry mucous membranes o Acanthosisnigricans GIT o Hepatotoxicity o Myopathy o Metabolic: Hyperglycemia, Hyperuricemia CVS: Arrhythmia, hypotension Ocular toxicity: Amblyopia (reversible)reduced vision in an eye not correctable by a manifest refraction; Maculopathy
Acanthosisnigricans Peptic ulcer/severe pepric disease Hepatic disease Diabetes mellitus Gout Pregnancy Patients on hypertensive therapy
Monitor serum levels of: glucose, aminotransferase, uric acid, albumin, CK Pharmacokinetics: Absorption almost complete Metabolism extensive Excretion urine mostly as metabolites; Doses daily vitamin requirement as antihyperlipideic T - 60 mins.
TG Cholesterol
Colestipol Cholestyramine Colesevelan
Binds bile acids in gut preventing reabsorption, increases cholesterol catabolism, up regulates receptors LDL Enhanced conversion of cholesterol to bile acid
absorption of - Folic acid - Drugs - Fat soluble vitamins GI: constipation, sensation of fullness, discomfort Hypoprothrombonemia Increase bleeding tendency Increase effects of anticoagulants Hypertriglyceridemia Hypertriglyceridemia Diverticulitis Hemorrhoids Biliary obstruction Large polymeric cationic exchange resins and insoluble in water
ANTI-HYPERTENSIVES
DRUGS THAT ALTER SNS FUNCTION A. Centrally acting Sympathoplegic drugs
rarely used - Methyldopa - Clonidine -Reduce sympathetic outflow from vasomotor center in brain -increase sensitivity to baroreceptor center Central adrenoceptor stimulation -Decrease TPR, HR, CO -Decrease renal vascular resistance - Block nicotinic receptors on postganglionic neurons of SNS and PNS -Inhibit release of NE from sympathetic nerves transported by NET -interferes with VMAT >depletes NE, dopamine, 5HT in central and peripheral nerve endings -only used pregnancy for HPN in -Dry mouth -sedation -depression -Lactation > prolactin secretion (Methyldopa) -HPN crisis > inc SNS activity (Clonidine withdrawal)
D. Adrenoceptor Antagonists
1. Beta Blockers - Decrease CO, TPR, HR - Propranolol Cardioselective: - Metoprolol Atenolol - Nadolol - Betaxolol - Bisoprolol Partial Agonists: - Pindolol - Acebutolol With blocker: Labetalol - Carvedilol - depress RAAS by blocking the intrarenal & extrarenal Breceptors involved in renin secretion - same as propranolol in B1 blockade but less potent B2 - less CO & HR depression than other B blockers - most widely used - long half lives > OD administration useful in pt with bradycardia & Peripheral Vasc Disease - tx of HPN in pt with pheochromocytoma and HPN crisis - tx ofpt with HF & HPN Bradycardia DM Peripheral vascular insufficiency
1st dose effect > occurs in salt & H2O depleted pt > reduce 1st dose & administer at h.s. Dizziness Headache Lassitude
B. Arteriovenous Sodium Nitroprusside Calcium Channel Blockers Dihydropyridine: - Nifedipine - Amlodipine Nicardipine - Nisoldipine > More selective vasodilator > Less cardiac depressant than Verapamil & - Diltiazem - Nimodipine: cerebral blood vessels
Activates guanylyl cyclase > inc intracellular cGMP > relaxed smooth muscle -bind to L-type Ca++ channel (heart smooth muscle) -decrease trans-membrane Ca++ current -smooth muscle relaxation -Decrease myocardial contractile force - decrease myocardial O2 requirement decrease HR (Verapamil, Diltiazem) -relief vasospasm in coronary artery RX: Angina pectoris -Decrease AV node conduction RX: Supraventricular tachycardia - AF Peripheral vasodilator RX: HPN - Raynauds phenomenon Nicardipine RX: Severe HPN thru IV
Cyanide Accumulation
- No effect on bradykinin Metabolism > more selective blocker of angiotensin effects than ACE inh Reduces plasma renin activity, aldosterone Greater anti HPN effect angiotensin I, II,
Same with ACE inh except for the cough and angioedema
ANTI-HYPERTENSIVES: DIURETICS
A. CARBONIC ANHYDRASE INHIBITORS Mechanism of Action
Acetazolamide
Adverse Effects
Hyperchloremic metabolic acidosis
Indications
Contraindications
Hepatic encephalopathy/hepatic coma/impaired liver function alkaline pH decreases urinary NH4 excretion
Other notes
Prototype drug Well-absorbed after oral administration
Acts on the proximal convoluted tubules where reabsorption of sodium bicarbonate occurs Sodium bicarbonate will be absorbed through the sodium-hydrogen
Glaucoma
Renal stones: decreased citrate excretion, Ca++ salt precipitation d/t presence of alkaline pH Renal potassium wasting Drowsiness
(Dorsolamide, Brinzolamide topical or eyedrop forms for organ selectivity) decreased formation of aqueous humor
Excretion of the drug is by secretion in the proximal tubule S2 segment Onset of action: 30 minutes to 2 hours
Metabolic alkalosis
exchanger Na ions will be reabsorbed into the interstitium of the kidneys while H will be secreted to the tubular lumen H ions will combine with bicarbonate to form carbonic acid Carbonic acid will dissociate to H2O and CO2 by the enzyme carbonic anhydrase Acetazolamide inhibits this enzyme No sodium ion will be reabsorbed due to the decreased ability to exchange Na with H ions Blocks sodium bicarbonate rabsorption Acts on the Loop of Henle, particularly in the thick ascending limb Inhibits Na-K-2Cl transporter in the thick ascending limb decreased NaCl, Mg, Ca reabsorption Increases renal blood flow useful for patients with decreased urine output Also shown to induce expression of COX-2 increased synthesis of prostaglandins (PGE2) from arachidonic acid inhibits salt transport in the thick ascending limb (this can be blocked by NSAIDs) Blocks NaCl transporter in the distal convoluted tubule inhibits NaCl reabsorption, but
Acute mountain
Urinary alkalinization:
Paresthesias Nervous system toxicity (seen in patients with renal failure) Allergic reactions
decreased bicarbonate reabsorption increased urinary pH enhanced excretion of weak acids Adjuvants in treatment of epilepsy, hypokalemic periodic paralysis, and in increasing urinary phosphate excretion during severe hypophosphatemia.
Duration: 12 hours 85% of the bicarbonate reabsorptive capacity of the proximal convoluted tubule is inhibited. Diuretic efficacy of acetazolamide decreases significantly with use over several days.
B. LOOP DIURETICS
Furosemide 20/40 mg tab; 20mg amp prototype drug Butenamide (Lasix) 1mg tab; 0.5mg amp Torsemide (not available locally) Ethacrynic Acid (not available locally)
Hypokalemia/Hypokalemi c Metabolic Acidosis Hypomagnesemia Ototoxicity (reversible) Hyperuricemia, gout (d/t increased reabsorption of uric acid in renal tubules secondary to hypervolemia) Allergic reaction diuretics sulfonamides) (loop are
Most effective type of diuretics because of the large sodium chloride absorptive capacity of the thick ascending limb effect is not diminuted by acidosis, unlike other types of diuretics Onset: 2-3 (furosemide); 1 (torsemide) hours hour
(increase rate of urine flow by increasing renal blood flow; increased K+ excretion)
Duration: 2-3 hours (furosemide); 4-6 hours (torsemide) Rapidly absorbed Eliminated by the kidney by glomerular filtration and tubular secretion Diuretic activity of loop diuretics correlates with their secretion by the proximal tubule.
C. THIAZIDES
Chlorothiazide Hydrochlorothiazide (12.5/25 mg tab) Indapamide (1.5mg tab)
Heart
increases Ca reabsorption Increase in calcium reabsorption is postulated to result from effects in both the proximal and distal convoluted tubules:
PCT:
thiazideinduced volume depletion enhanced Na+ and passive Ca++ reabsorption thiazideinduced blockade of Na entry decreased intracellular Na enhances Na-Ca exchange in the basolateral membrane increased Ca reabsorption
administered orally but there are differences in their metabolism: Chlorothiazide is not very lipid soluble and must be given in large doses; this is the only thiazide available for parenteral administration.
and decreased glucose utilization) Hyperlipidemia Dilutional hyponatremia (d/t ADH production secondary to hypovolemia) Allergy
DCT:
Nephrogenic
insipidus
diabetes
All thiazides are secreted by the organic acid secretory system in the proximal convoluted tubule and compete with the secretion of uric acid by that system thiazides may blunt uric acid secretion and elevate serum uric acid level. Usually combined with other drugs, such as beta blockers, ARBs, and ACE inhibitors to potentiate the effects of controlling blood pressure. There are drugs available that already have combined beta blocker/ARB/ACE inhibitor and diuretic effects. However, if diuretics are to be given with calcium channel-blockers, they should be given separately. Acute Renal Failure Hyperkalemia Liver disease Direct Antagonists of Aldosterone Receptors Spironolactone Synthetic steroid that acts as a competitive antagonist to aldosterone Substantial inactivation of spironolactone occurs in the liver Rather slow onset of action, requiring several days before full
D. POTASSIUM-SPARING DIURETICS
Spironolactone Eplerenone Amiloride Triamterene
K-sparing diuretics
prevent K+ secretion by antagonizing the effects of aldosterone at the late distal and cortical collecting tubules. direct pharmacologic antagonism of mineralocorticoid receptors (spironolactone, eplerenone) or by inhibition of Na+ influx through ion channels in the luminal membrane (amiloride, triamterene)
Hyperaldosteronism Primary Conns syndrome Secondary CHF, liver cirrhosis, nephrotic syndrome
Spironolactone and
eplerenone bind to mineralocorticoid receptors and blunt aldosterone activity. Amiloride and triamterene do not block aldosterone, but instead directly interfere with Na+ entry through the epithelial Na+ channels (ENaC) in the apical membrane of the collecting tubule. Since K+ secretion is coupled with Na+ entry in this segment, these agents are also effective potassium-sparing diuretics
therapeutic effect is achieved Eplerenone More selective: less active on androgen, progesterone receptors Spironolactone analog with much greater selectivity for the mineralocorticoid receptor Several hundredfold less active on androgen and progesterone receptors than spironolactone Fewer adverse effects Inhibitors of Na+ influx through ion channels in luminal membrane Amiloride Triamterene Metabolized in the liver, but renal excretion is a major route of elimination for the active form and the metabolites Because triamterene is extensively metabolized, it has a shorter half-life and must be given more frequently than amiloride (which is not metabolized)
Amiloride
E. OSMOTIC DIURETICS
and triamterene are direct inhibitors of Na+ influx in the CCT (cortical collecting tubule).
Mannitol
their major effect in the proximal tubule and the descending limb of Henle's loop. Through osmotic effects, they also oppose the action of ADH in the collecting tubule. Prevents the normal absorption of water by interposing a countervailing osmotic force resulting to increased urine volume.
Mannitol
Decreases intracranial pressure Decreases intraocular pressure Congestive heart failure Increased ECF volume Hyponatremia Dehydration
prototypic drug; the only osmotic diuretic available is poorly absorbed by the GI tract, and when administered orally it causes osmotic diarrhea. For systemic effect, mannitol must be given parenterally.
Mannitol
rate decreases the contact time between fluid and the tubular epithelium, thus reducing Na+ as well as water reabsorption.
F. ADH AGONISTS
Vasopresin Desmopresin Renal action appears to be mediated primarily via V2 receptors although V1a receptors may also be involved. ADH antagonists inhibit the effects of ADH in the collecting tubule Both lithium and demeclocycline appear to reduce the formation of cyclic adenosine monophosphate (cAMP) in response to ADH Central Diabetes Insipidus
ANTI-ANGINA
A. NITRATES Mechanism of Action
Nitroglycerin Isosorbide Dinitrate (ISDN) Nitrates will be removed of its nitrate group by Gluthatione S-Transferase
Adverse Effects
Hypotension because it is not only the coronary vessels that are dilated
Indications
Angina
Contraindications
Increased intracranial pressure
Other notes
Nitroglycerin considered as the prototype of the
which will release the free nitrate. The free nitrate will then be converted to nitric oxide. The nitric oxide causes activation of guanylylcyclase and an increase in cGMP which, in turn, would cause smooth muscle relaxation as stated in the previous mode of action.
but also the other blood vessels (peripheral blood vessels) Tachycardia Severe headache (due to vasodilation of cerebral vessels)
group not sensitive to sunlight but may lose its potency due to volatilization and adsorption to plastic surfaces, therefore it should be kept in a tightly closed glass containers Isosorbide dinitrate/mononitrate sublingual administration to prevent first pass effect in the liver
can also be given transdermally by placing a patch on any part of the chest or even in the abdomen; will be absorbed in the skin mucous membrane and will produce the therapeutic effect
Onset: 1-3 minutes Duration: 15-30 minutes Types of Administration: SL, Transdermal, SR 1-3 minutes of administration would provide immediate relief of the chest pain. If the chest pain is not relieved, wait for another 15 minutes then administer again (duration of action: 15-30 minutes). If the chest pain is not yet relieved by this, the patient must have a probable MI and should be admitted immediately to an ICU. Slow Release tablets: used as
Nicorandil
Trimetazidine
Ranolizine
Decreased myocardial contractility Decreased HR Other effects similar to calcium channel blockers
Ivabradine
MUCOKINETICS (EXPECTORANTS)
A. DIRECTLY-ACTING Mechanism of Action
Guaiphenesin/Guaifenesin Decrease sputum viscosity and increase sputum volume thereby decreasing
Adverse Effects
Nausea, gastric disturbances, drowsiness
Indications
Productive cough
Contraindications
Hypersensitivity
Other notes
Na+, K+ citrate/acetate
Na content H2O
content Cause irritative action on bronchial mucosa resulting to production of excess respiratory tract fluid w/c is easier to cough
B. REFLEXLY-ACTING
Nausea and vomiting Productive cough Irritant to gastric mucosa
Ammonium chloride
Potassium Iodide
Productive cough Depolymerizes polysaccharide directly as well as by liberating lysosomal enzymes w/c breaks down the fiber network in the tenacious sputum Makes the phlegm in the airway thinner and less sticky by increasing the bodys natural production of surfactant (anti-glue) Splits disulphide bonds linking proteins in the mucus thereby reducing mucus viscosity Liquefies viscid sputum
C. MUCOLYTIC
Rhinorrhea, lacrimation, gastric irritation Productive cough Hypersensitivity
Bromhexine
Ambroxol
Productive cough
Metabolite of Bromhexine
Acetylcysteine
Productive cough
Carbocisteine
Productive cough
ANTITUSSIVES
A. NARCOTIC ANTITUSSIVE Mechanism of Action
Codeine Directly suppresses cough center by binding to distinct receptors in medulla
Adverse Effects
(TD)Sedations, nausea, constipation Higher dose: respiratory depression, drowsiness Stupor, ataxia, respiratory depression, convulsion in children
Indications
Contraindications
Asthmatic px, px with diminished respiratory reserves
Other notes
Pholcodeine- has similar efficacy as codeine with longer duration (12hrs) with no analgesic or addictive property
Dry cough
B. NON-NARCOTIC ANTITUSSIVES
Dextromethorpan Depress cough center in medulla and increasing the threshold for cough Spasmodic cough children below 6 yrs., px taking MOA inhibitors A synthetic compound
Noscapine
Depress cough
Spasmodic cough
*Asthmatic patients
C. ANTI-HISTAMINICS
Chlorpheniramine Diphenhydramine Promethazine Sedative and anticholinergic action Urinary retention Blurred vision Drowsiness Nausea Vomiting Constipation Headache Lack selectivity for cough centers No efficacy in asthma
ANTI-ASTHMA
(ANTI-INFLAMMATORY CONTROLLERS) A. CORTICOSTEROIDS
ORAL: A. Reduce airway reactivity Mechanism of Organ System Prednisone , Methyprednisolone (dose Increase airway Action diameter depend on severity) INHALED: Terbutaline Inhibit lymphocytic, Budesonide, Fluticasone (Long Acting q 12 Albuterol eosinophilic airway hrs) Salbutamol mucosal Promotes bronchodilation inflammation Fenoterol Reduce frequency of Activate G protein asthma cAMP intracellular Ca attacks Formoterol Potentiate effects of Salmeterol 2 agonists
Mechanism of Organ System Adverse Indications ANTI-ASTHMA Effects Action (BRONCHODILATOR RELIEVERS AND CONTROLLERS) Effects
Contraindication s
Other Notes
effective in improving all indices of asthma Other notes controlseverity of symptoms, tests of R isomer activate beta airway caliber and bronchial receptorreactivity, frequency causes S isomer of exacerbations, inflammation and quality of life Long acting Corticosteroid + LABA No anti-inflammatory (Long Acting 2 property Agonist) ( inhaled)
2 AGONISTS
Effect Adverse
Indications
Contraindications
B. SYMPATHOMIMETIC
Epinephrine Bronchodilation CV: vasoconstriction
C. MUSCARINIC ANTAGONISTS
Atropine
Hoarseness advise to drink Throbbing headache, gurgle H20 or Tremors, tachycardia, Asthma after inhaler palpitation Adrenal insufficiency best time 8am to mimic diurnal Tachycardia, arryhtmia, variation worsening of angina Status asthmaticus pectoris Slow growth rate children
Budesonide + Formeterol mins. Onset- 15 Duration- 60-90 mins. + Fluticasone Salmeterol (Seretide) Prototype drug Only have partial reversible property for COPD Inhibits M3 receptors prevent Leukotriene synthesis Approved as treatment for Prevent LT action COPD Bronchoconstriction, bronchial reactivity, mucosal edema, mucus hypersecretion Narrow therapeutic window Less potent and shorter Cromolyn poorly absorbed from acting than theophylline the gastrointestinal tract and must be inhaled as a microfine powder or aerosolized solution. Nedocromil also has a very low bioavailability and is available only in metered-dose aerosol form.
5 lipoxygenase inhibitor ( not available ) receptors Zileuton Tiotropium LTD4 receptor Antagonist Montelukast, Zafirlukast (available in D. market) METHYLXANTHINES Uncertain: Res: bronchodilation phosphodiesterase CV: cardiac stimulation inhibition, adenosine Musculoskeletal: increased C. Theophylline STABILIZERS MAST CELL receptor antagonist skeletal INHALED: inhibits degranulationmuscle strength (Katzung) (diaphragm) Na Cromoglycate of mast cell (inhibits Competitive nonselective & serotonin) histamine PDE inhibitor Res: bronchodilation Cromolyn, Nedocromil Inhibit antigen, Aminophylline IV Non selective adenosine exerciseinduced receptor antagonist asthma, slightly bronchial reactivity Inhibit mast cell degranulation Produces an alteration in the function of delayed chloride channels in the cell membrane, inhibiting cell activation. This action on airway nerves is thought to be responsible for nedocromil's inhibition of cough; on mast cells, for inhibition of the early response to antigen challenge; and on eosinophils, 2D Section for inhibition of the inflammatory response to inhalation of allergens
Dizziness, intraocular pressure, tachycardia Anorexia, nausea, vomiting, abdominal discomfort, anxiety, headache, seizures, arrhythmias, insomnia
Asthma, COPD Aspirin-induced asthma Bronchial asthma allergic rhinoconjunctiv itis Applying the solution by nasal spray or eye drops several times a day is effective in about 75% of patient
are minor and are localized to the sites of deposition. throat irritation cough mouth dryness rarely, chest tightness, and wheezing
Batch 2014
can be prevented by inhaling a 2adrenoceptor agonist before cromolyn or nedocromil treatment Serious PHARMACOLOGY: adverse Page 22 of 29 effects are rare Reversible dermatitis,
AUTACOIDS Role Found in skin, GI mucosa, lungs, liver, placenta, brain Mediator of immediate allergic & inflammatory reactions Gastric acid secretion MOA Binds with membrane receptors: H1 *smooth muscle *endothelium H2 *gastric mucosa *cardiac muscle *brain *immune cells H3 *pre-synaptic brain *myenteric plexus H4 *eosinophils *neutrophils *CD4T cells Organ System Effects 1. HISTAMINE CNS *stimulate sensory nerve endings (pain, itch) CVS *vasodilatation * (+) inotropy * (-) chronotropy *fluid transudation RS *bronchoconstriction (H1) GIT *increased intestinal motility * increased gastric acid * increased pepsin *Intrinsic Factor secretion Antagonists I. Physiologic Antagonist Epinephrine II. Inhibitors of Histamine Release Cromolyn, Nedocromil, 2 agonists inhibits degranulation of mast cells III. Histamine Receptor Antagonist A. H1 Receptor Antagonists (1st Generation) for hypersensitivity reactions 1. Sedation (1st generation, side Highly sedative effect) Diphenhydramineq6-8 Dimhenhydrinateq8 Promethazine (parenteral) Hydroxyzine (itarax) LA Moderately Sedative Buclizine (appetite stimulant) Cinnarizine (vertigo/motion sickness) Meclizine Pheniramine Cyproheptadine Mild Sedative Chlorpheniramine Clemastine LA Dimethidine Methdilazine NA Mepyramine NA Triprolidine NA Cyclizine NA Rx: Scopolamine (not available) Promethazine (IM) Dimenhydrinate Cyclizine Meclizine (Bonamine) Betahistine Cenarizine Rx: Diphenhydramine High anti-cholinergic action Promethazine Diphenhydramine (Benadryl) Dimenhydrinate Pheniramine Cyproheptadine Low anti-cholinergic action Chlorpheniramine Hydroxyzine Cyclizine Meclizine
3.Anti-Parkinsonism suppress extrapyramidal symptoms 4.Anti-cholinergic urinary retention, blurred vision (side effects)
Minimal/ absent anti-cholinergic action Clemastine Terfenadine (arrhythmia effect) Astemizole Loratidine (Alerta) Ebastine Cetirizine Rx: Promethazine (should be in supine postion) Cyproheptadine (appetite stimulant)
7.Allergy Urticaria, Allergic rhinitis Side Effects/Toxicity Sedation, decreased alertness & concentration, motor incoordination, light-headedness, dryness of mouth, urinary hesitancy, blurring of vision Cyclizine, Meclizine teratogenic B. H1 Blockers (2nd generation) Loratadine Higher H1 selectivity Desloratadine No anti-cholinergic side Cetirizine inhibits H release & cytotoxic mediators from platelets & effects eosinophil chemotaxis no CNS depressant property Azelastine (Do not potentiate alcohol, Ebastine benzodiazepine) Terfenadine blocks cardiac K+ channels (overdose); Torsades de Inhibit late phase allergic pointes reaction by acting on LT, antiFexofenadine no arrhthymogenic potential platelet activating effect Poor anti-pruritic, antiemetic, anti-tussive properties Used for: Allergic rhinitis, conjunctivitis, hay fever, urticaria, atopic eczema, acute allergic reactions C. H1 Blockers (3rd generation) Levocetirizine D. H2 Blockers Anti-ulcer Cimetidine Cytochrome P450 inhibitor, anti-androgen effects Ranitidine Famotidine Nizatidine
Major source in intestines (90%) Platelets Brainstem (mood, sleep, appetite, pain perception,
CNS *Vomiting *Pain *Itch *Bezold-Jarisch reflex (5HT3) *chemoreceptor reflex marked outflow of vagal stimulation to the heart bradycardia
SEROTONIN I. Serotonin (5-HT) Agonists A. 5HT1A Receptor Buspirone (anxiolytic) B. 5HT1D Receptor Amlotriptan NA Sumatriptan Zolmitriptan (constrict cerebral vessel)(migraine headache) C. 5HT4-Cisapride(toxic) Tegaserod (partial agonist) irritable bowel syndrome
CVS *vasoconstriction (5HT2) except skeletal muscle, heart *platelet aggregation RS *bronchoconstriction (5HT2) GIT *increases motility thru ACh (5HT4) Skeletal muscles *serotonin syndrome (5HT2) *hyperthermia
II. Serotonin (5-HT) Antagonists 1. 5HT1-5HT2 2. 5HT2 3. 5HT2, H1 4. 5HT3 Therapeutic Uses 1. controls S/S carcinoid, post-gastrectomy dumping syndrome 2. Raynauds disease 3. Anti-emetic (anti-cancer, radiotherapy) 4. Migraine prophylaxis, Carcinoid, post-gastrectomy dumping syndrome 5. Migraine (better tolerated) 6. Schizophrenia
Synthesized
from tryptophan
Methysergide Ketanserin blocks platelet aggregation for stroke Ritanserindecreases thromboxane formation for stroke Cyproheptadin for cold-induced urticaria for carcinoid syndrome Ondansetron chemotherapy-induced nausea & vomiting Cyproheptadine sedative, stimulates appetite, good anti-pruritic Ketanserin blocks platelet aggregation for stroke Ritanserindecreases thromboxane formation for stroke Ondansetron Methysergide Sumatriptan Zolmitriptan Risperidine Clozapine
Degraded by
ERGOT ALKALOIDS
Mechanism of Action Organ System Effect Adverse Effects Indications Contraindications Other notes
Amine Alkaloids Ergometrine Ergonomine Amino Acid/Peptide Alkaloids Ergotamine Regotoxine Semi-Synthetic Alkaloids Ergometrine Ergonomine
agonist, partial agonist, antagonist at receptors, serotonin receptors, CNS dopamine receptors
CNS powerful hallucinogen (Lysergic Acid Diethylamide or LSD) Bromocriptine inhibits prolactin CVS vasoconstriction d/t partial agonist effects at adrenoceptors
Nausea, vomiting (high dose) Prolonged vasospasm gangrene, bowel infarction Drowsiness, hallucinations
Ergotamine, Ergonovine, Methysergide migraine headache (partial agonist & 5HT2) Uterus postpartum hemorrhage, induces labor Ergonovine, Oxytocin (parenteral), Methylergometrine (Methergine) parenteral or oral
EICOSANOIDS
Mechanism of Action
Arachidonic Acid Arachidonic Acid Oxygenated by 4
Adverse Effects
Indications
Contraindicati ons
Other notes
Lipid-derived autacoids Oxygenation products of polyunsaturated long chain
TXA2, PGF2
Prostaglandins
routes:
Lipoxygenase: HETEs, leukotrienes, lipoxins Cytochrome P450 (epoxygenase) EETs, vasodilator Icoeicosanoid: Isoprostane, vasoconstrictor Cyclooxygena se: PG, prostacyclin, thromboxane
GIT
PGI2/prostacyclin, PGE1 vasodilatation, bronchodila, relaxes uterus Epoprostenol (PGI2) pulmonary HPN Alprostadil (PGE1) patency of DA COX inhibitor (Indomethacin) closes ductus arteriosus Misoprostol/cytotec (PGE1) for peptic ulcer (NSAID- induced), for abortion
Eicosanoid Inhibitors
Corticosteroids: Non-Steroidal
inhibits all pathways by stimulating synthesis of inhibitory protein, inhibit phospholipase A prevent arachidonic acid release Anti-Inflammatory Drugs (NSAIDs): blocks prostaglandin & thromboxane formation by inhibiting cyclooxygenase activity Aspirin (Acetylsalicylic Acid) irreversible acetylation of platelet cyclooxygenase (other drugs not irreversible); inhibits TXA2 synthesis
PGH synthase-1 (COX1): gastric epithelial protection PGH synthase-2 (COX2): source in inflammation
Enprostil NA (PGE) inhibit HCl secretion Respiratory System PGE2, PGI2 bronchodilatation PGD2, TXA2 bronchoconstriction
Indications: transient ischemic attack (TIA), CAD (coronary artery disease) Adverse Effects: Gastric/duodenal ulcer Hepatotoxic Allergy (most common)
PGF2, LT bronchoconstriction Platelet aggregation PGD2, PGE2, PGI2 inhibit TXA2 stimulate
Pyrazone Oxybutazone
Phenylbutazone,
Indole Indomethacin, Sulindac Propionic acid Ibuprofen, Naproxen, ketoprofen Anthranilic acid Mefenamic acid Aryl-acetic acid Diclofenac Oxicam Piroxicam, Tenoxicam
Pyrolopyrole Ketorolac COX-2 Selective Inhibitors Mechanism of action: bind to and block active site of COX2 enzyme (reversible) Less GI effects, no platelet effect Adverse Effects: Fluid retention Hypertension Hepatotoxic Nephrotoxic Rashes
PGF2, PGE2- uterine contraction, soften cervix Dinoprostone, Misoprostol, Carboprost PGE2, PGF2 SE dysmenorrhea (take NSAIDs)
Alprostadil (PGE1) relax smooth muscle of corpora cavernosa for erectile dysfunction lipooxygenase, P450
GIT
12Hydroxyeicosatetrae noic (HETE) chemoattractant for smooth muscles LTC4, LTD4 myocardial depressant, constriction of coronary arteries
LTB4 chemoattractant for PMNs Respiratory LTC4, LTD4 bronchoconstriction, mucus secretion, plasma exudation Blood LTB4 chemoattractant for T cell, eosinophils, monocytes, mast cells Renal System
20 HETE vasoconstriction
VASOACTIVE PEPTIDES
ANGIOTENSIN RECEPTOR ANTAGONISTS Mechanism of Action Valsartan
Selective antagonist of AT1 receptors competitive angiotensin
Adverse Effects
Indications
Hypertension
Contraindications
Other Notes
Eprosartan, irbesartan, candesartan, olmesartan, telmisarta - similar to valsartan
CONVERTING ENZYME INHIBITORS Mechanism Action Enalapril RENIN INHIBITORS Mechanism Action Aliskiren KININ ANTAGONISTS Mechanism Action Icatibant
of
Adverse Effects
Indications
Hypertension heart failure
Contraindications
Other Notes
Captopril and many others -similar to enalapril
of
Adverse Effects
Indications
Hypertension
Contraindications
Other Notes
of
Adverse Effects
Indications
Potential use for inflammatory pain and inflammation
Contraindications
Other Notes
of
Adverse Effects
Indications
Vasodilatory shock
Contraindications
Other Notes
Terlipressin - more selective for V1 receptor
of
Adverse Effects
Indications
Potential use in hypertension and heart failure hyponatremia
Contraindications
Other Notes
Relcovaptan increased selectivity for V1 receptor
of
Adverse Effects
Indications
Heart failure
Contraindications
Other Notes
PHARMACOLOGY: COMPREHENSIVE TABLE OF DRUGS (1st Shifting Period) | Page 28 of 29 Adverse Effects Indications Contraindications Other Notes
NITRIC OXIDE
Mechanism of Action Organ System Effects
1.
Adverse Effects
Indications
Contraindications
Other Notes
Nitric Oxide
blood vessels vasodilator inhibits PMN adhesion to endothelium 2. respiratory system relax smooth muscles NO activates soluble for pulmonary hypertension guanylyl cyclase to elevate and ARDS cGMP levels in vascular 3. platelets smooth muscle inhibits platelet adhesion, Jamie Juria Section 2D Batch 2014 aggregation, enhance fibrinolysis 4. CNS modifies NT release, learning & brain development
Methemoglobinemia
Inhaled gas